<DOC>
	<DOCNO>NCT02138734</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , dose-finding , multicenter study intravesical BCG plus ALT-803 Non-muscle invasive bladder cancer .</brief_summary>
	<brief_title>QUILT-2.005 : A Study Intravesical BCG Combination With ALT-803 Patients With Non-Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description>The purpose study evaluate safety , identify Maximum Tolerated Dose ( MTD ) ALT-803 determine Recommended Dose ( RD ) level ALT-803 combine BCG patient nonmuscle invasive bladder cancer . The anti-tumor activity BCG+ALT-803 also assess . In addition , study characterize molecular , immunogenicity pharmacokinetic profile BCG+ALT-803 . The study include dose escalation phase ( Phase Ib ) expansion phase ( Phase II ) . The dose escalation phase conclude MTD determine . A dose level ( RD ) designate phase II study . For noncomparative randomize phase II , patient randomize two treatment arm : either ALT-803 RD level combination BCG ( 50 mg ) BCG ( 50 mg ) alone .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>ENTRY CRITERIA : DISEASE CHARACTERISTICS : Histologic confirmation nonmuscle invasive bladder cancer transitional cell carcinoma highrisk subtype . ◦High risk define highgrade Ta T1 , CIS . No evidence muscleinvasive bladder cancer regional and/or distant metastasis . PRIOR/CONCURRENT THERAPY : No prior BCG treatment . No concurrent use investigational agent . PATIENT CHARACTERISTICS : Performance Status • ECOG 0 , 1 , 2 . Bone Marrow Reserve Absolute neutrophil count ( AGC/ANC ) ≥ 1,000/uL Platelets ≥ 100,000/uL Hemoglobin ≥ 8g/dL Renal Function Glomerular Filtration Rate ( GFR ) &gt; 40mL/min serum creatinine ≤ 1.5 x ULN Hepatic Function Total bilirubin ≤ 2.0 X ULN AST , ALT , ALP ≤ 3.0 X ULN Cardiovascular No symptomatic congestive heart failure &lt; 6 month . No severe/unstable angina pectoris &lt; 6 month . No myocardial infarction &lt; 6 month . No NYHA Class &gt; II . No mark baseline prolongation QT/QTc interval . Pulmonary • Adequate pulmonary function without clinical sign severe pulmonary dysfunction . Other Currently eligible intravesical BCG therapy . Negative serum pregnancy test female childbearing potential . No woman pregnant nursing . Subjects , female male , reproductive potential must agree use effective contraceptive measure duration study . No known autoimmune disease correct hypothyroidism ( phase Ib ) . No prior organ allograft allogeneic transplantation ( phase Ib ) . No known positive HIV status . No history evidence uncontrollable CNS disease . No psychiatric illness/social situation would limit compliance study requirement . No illness opinion investigator would exclude patient participate study . Must provide sign informed consent HIPPA authorization agree comply protocolspecified procedure followup evaluation . No active systemic infection require parenteral antibiotic therapy . No ongoing chronic systemic steroid therapy require . No concurrent febrile illness , active urinary tract infection , active tuberculosis , history hypotension anaphylactic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>antitumor</keyword>
	<keyword>BCG</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>instillation</keyword>
	<keyword>interleukin-15</keyword>
	<keyword>intravesical</keyword>
	<keyword>naive</keyword>
	<keyword>non-muscle invasive</keyword>
	<keyword>transitional cell carcinoma</keyword>
</DOC>